Physician profile
Danielle Shelton
NPI 1326309121
$2,397.30
in general payments reported to CMS, 2019-2025
34 companies · $51.31 in 2025
The $51.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $328 · 2021: $292 · 2022: $494 · 2023: $672 · 2024: $140 · 2025: $51.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $419.63 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $296.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $224.23 | 2021-2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $171.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $111.05 | 2020-2024 | Spravato |
| Abbvie INC. | $109.01 | 2021-2023 | |
| Lilly USA, LLC | $98.06 | 2020-2023 | Jardiance |
| Boston Scientific Corporation | $86.61 | 2022-2023 | |
| Pfizer INC. | $79.77 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $77.19 | 2019-2024 | |
| Abbott Laboratories | $63.92 | 2022-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $45.55 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $45.34 | 2019-2020 | |
| Amgen INC. | $42.85 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.77 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $37.56 | 2022-2024 | |
| Horizon Therapeutics Plc | $36.49 | 2022-2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $34.74 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $34.58 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.40 | 2019-2022 | |
| Astellas Pharma US INC | $29.41 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.70 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.83 | 2022-2023 | Eliquis |
| Masimo Corporation | $27.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.69 | 2022 | |
| Insulet Corporation | $22.92 | 2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $20.22 | 2023 | |
| Shield Therapeutics INC | $19.82 | 2023 | Accrufer |
| Cardiovascular Systems INC. | $19.82 | 2020 | |
| Exact Sciences Corporation | $18.18 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $18.02 | 2023 | Korlym |
| Medtronic, INC. | $14.33 | 2023 | Closurefast |
| Arbor Pharmaceuticals, INC. | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Shelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.